Clinical trials: Transmission
HIV Infections
A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine
This study will see how safe and effective against HIV the drugs L-756423 plus indinavir (IDV) are compared to just IDV when taken with stavudine (d4T) and lamivudine (3TC).
- Trial name
- NCT00002424
- Testing
- L-756423, Indinavir sulfate, Lamivudine
- Where
- 16 sites in United States
- Volunteers
- 186 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphatic Disease, HIV Infections
The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node Disease
The objective of this Phase III, randomized, double-blind, placebo-controlled study in patients with immunologic deficiency is to determine the effect of Isoprinosine in producing an immuno-restorative response within the study…
- Trial name
- NCT00002296
- Testing
- Inosine pranobex
- Where
- United States
- Sponsor
- Newport Pharmaceuticals International
AIDS
Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons
This study is designed to determine whether administration of the GSK Biologicals HIV vaccine 732462 can lead to a reduction in viral load, and impact on the course of human immunodeficiency virus type 1 (HIV-1) infection.
- Trial name
- NCT01218113
- Testing
- GSK Biologicals HIV Vaccine 732462
- Where
- 42 sites in United States, France and 2 more
- Volunteers
- 191 people
- Sponsor
- GlaxoSmithKline
Sarcopenia
Investigating Loss of Neuromuscular Junction Transmission Fidelity in Older Adults
Sarcopenia is a condition characterised by age-related loss of muscle mass and function. Factors affecting the strength of muscle contraction independent of mass, such as neuromuscular junction (NMJ) transmission, are…
- Trial name
- STAMINA (NCT04904926)
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- NMD Pharma A/S
Opioid Withdrawal
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
This Phase 1b/2 inpatient study assessed the safety, pharmacokinetics, and early signs of efficacy of escalating doses of BXCL501 versus placebo following discontinuation of morphine maintenance.
- Trial name
- NCT04470050
- Testing
- Dexmedetomidine
- Where
- 3 sites in United States
- Volunteers
- 225 people
- Sponsor
- BioXcel Therapeutics Inc
HIV Infections
A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
The purpose of this study is to see if it is safe and effective to give 1592U89 plus certain protease inhibitors (PIs) to HIV-infected patients who never have been treated with anti-HIV drugs.
- Trial name
- NCT00002440
- Testing
- Indinavir sulfate, Ritonavir, Abacavir sulfate
- Where
- 8 sites in United States
- Volunteers
- 80 people
- Sponsor
- Glaxo Wellcome
Chlamydia Trachomatis Infection, Neisseria Gonorrhoeae Infection
A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections
This study is designed to assess the comparative clinical utility of the point of care cobas® liat CT/NG/MG to current standard practices in the diagnosis and treatment of urogenital infections with Chlamydia trachomatis (CT)…
- Conditions
- Chlamydia Trachomatis Infection, Neisseria Gonorrhoeae Infection, Mycoplasma Genitalium Infection
- Trial name
- NCT06369220
- Testing
- cobas® liat CT/NG/MG nucleic acid test, Standard of Care (SOC): Clinician's Standard Practice
- Where
- 4 sites in United States
- Volunteers
- 331 people
- Sponsor
- Hoffmann-La Roche
Human Immunodeficiency Virus (HIV)
A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body
To investigate the pharmacokinetics of PF-04776548 following administration of a micro-dose of PF-04776548 via both intravenous and oral routes.
- Trial name
- NCT01045317
- Testing
- PF-04776548
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Pfizer
Common Warts, HPV (Human Papillomavirus)
Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)
Warts are benign epidermal tumors caused by human papillomaviruses (HPVs). The active pharmaceutical ingredient DPCP has been used for many years as a compounded formulation in acetone for the treatment of warts, alopecia areata…
- Conditions
- Common Warts, HPV (Human Papillomavirus), Periungual Warts, Plantar Warts
- Trial name
- NCT02640820
- Testing
- Sensitizing DPCP Ointment, Treatment DPCP Ointment
- Where
- 4 sites in United States
- Volunteers
- 83 people
- Sponsor
- RXi Pharmaceuticals, Corp.
HIV Infections
Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC
PRIMARY: To determine the efficacy and toxicity of three treatment regimens: saquinavir mesylate (Ro 31-8959) plus zidovudine (AZT) vs. AZT plus zalcitabine (dideoxycytidine; ddC) vs. Ro 31-8959 plus AZT plus ddC.
- Trial name
- NCT00001040
- Testing
- Saquinavir, Zidovudine, Zalcitabine
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Safety and Effectiveness of a Combination Anti-HIV Drug Treatment
The purpose of this study is to see if it is safe and effective to give HIV-positive patients a combination of anti-HIV drugs (abacavir [ABC] plus efavirenz [EFV] plus didanosine [ddI]) with and without hydroxyurea (HU).
- Trial name
- NCT00005018
- Testing
- Hydroxyurea, Abacavir sulfate, Efavirenz
- Where
- 23 sites in United States
- Volunteers
- 150 people
- Sponsor
- Glaxo Wellcome
Contraceptive, Sexually Transmitted Diseases
Synthetic Male Condom Slippage-Breakage Study
This is a multi-site, double-blind, crossover, randomized phase II study to evaluate the functional performance of a synthetic male condom as compared to a marketed latex condom.
- Trial name
- NCT05370196
- Testing
- Test Product, Control Product
- Where
- 2 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Church & Dwight Company, Inc.
HIV Infections
PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)
The purpose of this study is to determine whether atazanavir powder combined with ritonavir is safe and well tolerated and produces appropriate drug exposure in children ≥3 months to <6 years of age.
- Trial name
- PRINCE1 (NCT01099579)
- Testing
- Atazanavir powder, Ritonavir oral solution, Atazanavir capsules
- Where
- 18 sites in Brazil, Chile and 4 more
- Volunteers
- 82 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Liver Cirrhosis
Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)
This is a Phase 3b, randomized, open-label, parallel-group, multi-center, multi-national study of low-dose maintenance Peg interferon alpha-2b (Peg-Intron®) in subjects with human immunodeficiency virus-hepatitis C virus…
- Conditions
- Hepatitis C, Liver Cirrhosis, HIV Infections
- Trial name
- NCT00381017
- Testing
- Peg interferon alpha-2b
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants
The purpose of this study is to evaluate the safety, acceptability, pharmacokinetics (what the body does to the medication), and ex vivo (tested outside the body) pharmacodynamics (what the medication does to the body) of TMC278…
- Trial name
- NCT01656018
- Testing
- TMC278, Long acting (LA)
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
HIV Infection
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
The purpose of this study is to monitor adverse events in HIV-infected children <18 years old who are exposed to Atazanavir in a real-world setting in Europe.
- Trial name
- NCT01389310
- Where
- 9 sites in Belgium, Germany and 5 more
- Volunteers
- 249 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects
Racivir ® (RCV) is an experimental drug which means it is not approved for use by the United States Food and Drug Administration (FDA), but it can be used in research studies like this one.
- Trial name
- NCT00121979
- Testing
- Racivir, a non-nucleoside reverse transcriptase inhibitor
- Where
- 6 sites in United States, Argentina and 2 more
- Volunteers
- 60 people
- Sponsor
- Pharmasset
Pertussis
Assessing Contacts' Decision Making on Reducing the Risk of Pertussis Transmission to Newborns Through Immunisation
This study aims to establish an effective method to inform parents or close relatives of newborns about the risk of pertussis transmission to newborns and the advantages offered by the cocooning strategy (vaccinating those who…
- Trial name
- NCT01890447
- Testing
- Web-based survey questionnaire
- Where
- 9 sites in Italy, Spain
- Volunteers
- 676 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV InfectioN, HPV-Related Carcinoma
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-45 Years
A total of 13500 Chinese women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 35-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1.
- Trial name
- NCT05262010
- Testing
- 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- Where
- 8 sites in China
- Volunteers
- 13,500 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
HIV Infections
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
To evaluate changes in renal function, efficacy, and safety when switching from a combination of tenofovir/emtricitabine (TDF/FTC) plus a protease inhibitor/ritonavir (PI/r) to a combination of raltegravir (MK-0518) plus…
- Trial name
- RANIA (NCT02116660)
- Testing
- Raltegravir (MK-0518), Nevirapine, Lamivudine
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.